Floatz logo

Donafenib

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Peking Union Medical College HospitalSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Extensive-stage Small Cell Lung Cancer (ES-SCLC) cohort.

Asset / SponsorPhaseRating
MEGESTROL ACETATE IMPURITY B
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3BB
Nano-Crystalline Megestrol Acetate Suspension
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3B
Nanocrystalline Megestrol Acetate Suspension
Guangzhou Institute of Respiratory Disease
Phase 2CCC
Ligufalimab
Akeso
Phase 2CCC
Tafolecimab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2CCC
Teniposide
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2CCC
dji136
Novartis Pharmaceuticals
Phase 1/2CC

Same molecule, other indications

Donafenib is also rated in:

hepatocellular carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
DonafenibDormant
B
Indicative ·
62 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →